Jazz Pharmaceuticals plc

NasdaqGS:JAZZ Lagerbericht

Marktkapitalisierung: US$7.7b

Jazz Pharmaceuticals Management

Management Kriterienprüfungen 3/4

Jazz Pharmaceuticals CEO ist Bruce Cozadd , ernannt in Jan 2003, hat eine Amtszeit von 21.83 Jahren. Die jährliche Gesamtvergütung beträgt $15.34M , bestehend aus 7.8% Gehalt und 92.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.52% der Aktien des Unternehmens, im Wert von $39.92M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.2 Jahre bzw. 11.5 Jahre.

Wichtige Informationen

Bruce Cozadd

Geschäftsführender

US$15.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts7.8%
Amtszeit als Geschäftsführer21.8yrs
Eigentum des Geschäftsführers0.5%
Durchschnittliche Amtszeit des Managements5.2yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder11.5yrs

Jüngste Management Updates

Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Jul 18
Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Recent updates

Jazz Pharmaceuticals: High Uncertainty, Low Risk

Nov 18

We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve

Nov 14
We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Oct 22
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook

Oct 16

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 25
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst

Sep 19

Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Jul 18
Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jun 23
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues

Jun 21

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

Apr 15

Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Apr 02
Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Feb 18
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Updated View On Jazz Pharmaceuticals' 2025 Goals

Jan 29

Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Dec 26
Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Oct 31
Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jul 12
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Apr 12
We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Bruce Cozadd im Vergleich zu den Einnahmen von Jazz Pharmaceuticals verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

US$463m

Jun 30 2024n/an/a

US$395m

Mar 31 2024n/an/a

US$331m

Dec 31 2023US$15mUS$1m

US$415m

Sep 30 2023n/an/a

US$80m

Jun 30 2023n/an/a

-US$87m

Mar 31 2023n/an/a

-US$156m

Dec 31 2022US$17mUS$1m

-US$224m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$52m

Mar 31 2022n/an/a

-US$450m

Dec 31 2021US$16mUS$1m

-US$330m

Sep 30 2021n/an/a

-US$161m

Jun 30 2021n/an/a

US$40m

Mar 31 2021n/an/a

US$518m

Dec 31 2020US$13mUS$1m

US$239m

Sep 30 2020n/an/a

US$179m

Jun 30 2020n/an/a

US$133m

Mar 31 2020n/an/a

US$280m

Dec 31 2019US$15mUS$1m

US$523m

Sep 30 2019n/an/a

US$609m

Jun 30 2019n/an/a

US$656m

Mar 31 2019n/an/a

US$486m

Dec 31 2018US$11mUS$979k

US$447m

Sep 30 2018n/an/a

US$520m

Jun 30 2018n/an/a

US$434m

Mar 31 2018n/an/a

US$447m

Dec 31 2017US$10mUS$950k

US$488m

Vergütung im Vergleich zum Markt: BruceDie Gesamtvergütung ($USD15.34M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD7.74M).

Entschädigung vs. Einkommen: BruceDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Bruce Cozadd (60 yo)

21.8yrs

Amtszeit

US$15,341,235

Vergütung

Mr. Bruce C. Cozadd serves as an Independent Director of Acelyrin, Inc. since March 7, 2022 and also serves as its Chairman of Board since January 2023. He served as Member of Board of Advisors at Cellares...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Bruce Cozadd
Co-Founder21.8yrsUS$15.34m0.52%
$ 39.9m
Renee Gala
President & COO1.1yrsUS$5.43m0.028%
$ 2.1m
Patricia Carr
Senior VP & Chief Accounting Officer5.3yrsUS$1.40mkeine Daten
Neena Patil
Executive VP & Chief Legal Officer5.3yrsUS$3.88m0.012%
$ 934.2k
Robert Iannone
Executive VP5.5yrsUS$4.98m0.047%
$ 3.6m
Philip Johnson
Executive VP & CFOless than a yearkeine Daten0.020%
$ 1.5m
Andrea Flynn
VP & Head of Investor Relationsno datakeine Datenkeine Daten
Heidi Manna
Executive VP & Chief People Officer6yrskeine Datenkeine Daten
Jed Black
Senior Vice President of Sleep & CNS Medicineno datakeine Datenkeine Daten
Samantha Pearce
Executive VP & Chief Commercial OfficerChief Commercial Officer4.7yrskeine Daten0.011%
$ 811.0k
John Miller
Senior Vice President of Corporate Strategy5.2yrskeine Datenkeine Daten
Mary Henderson
Senior Vice President of Technical Operations1.3yrskeine Daten0.0021%
$ 162.3k

5.2yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrenes Management: JAZZDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.2 ).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Bruce Cozadd
Co-Founder21.8yrsUS$15.34m0.52%
$ 39.9m
Kenneth O'Keefe
Independent Director20.8yrsUS$513.77k0.046%
$ 3.5m
Seamus Mulligan
Independent Director12.8yrsUS$531.27k1.93%
$ 148.1m
Norbert Riedel
Independent Director11.5yrsUS$533.77k0.020%
$ 1.5m
Patrick Gerald Enright
Independent Director15.3yrsUS$526.27k0.035%
$ 2.7m
Patrick Kennedy
Independent Directorless than a yearkeine Datenkeine Daten
Rick Winningham
Lead Independent Director14.5yrsUS$571.27k0.015%
$ 1.1m
Jennifer Cook
Independent Non-Executive Director3.9yrsUS$533.77k0.0089%
$ 684.6k
Laura Hamill
Independent Directorless than a yearkeine Daten0.0025%
$ 189.9k
Heather McSharry
Independent Director11.5yrsUS$543.77k0.025%
$ 1.9m
Mark Smith
Independent Non-Executive Director3.9yrsUS$521.27k0.0089%
$ 684.6k
Anne O'Riordan
Independent Director5.8yrsUS$523.77k0.018%
$ 1.4m

11.5yrs

Durchschnittliche Betriebszugehörigkeit

61.5yo

Durchschnittliches Alter

Erfahrener Vorstand: JAZZDie Vorstandsmitglieder sind sehr erfahren ( 11.5 ).